ABVC Biopharma Inc Asset Resilience Ratio
ABVC Biopharma Inc asset resilience ratio. ABVC Biopharma Inc (ABVC) has an Asset Resilience Ratio of 0.32% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of ABVC Biopharma Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ABVC Biopharma Inc (2017–2025)
Asset resilience ratio of ABVC Biopharma Inc from 2017 to 2025. This chart shows how ABVC Biopharma Inc's Asset Resilience Ratio has changed over time. Read ABVC Biopharma Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ABVC Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is ABVC Biopharma Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.42K | 0.32% |
| Total Liquid Assets | $62.42K | 0.32% |
Asset Resilience Insights
- Limited Liquidity: ABVC Biopharma Inc maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ABVC Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare ABVC Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ABVC Biopharma Inc Asset Resilience Ratio by Year (2017–2025)
ABVC Biopharma Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for ABVC Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.31% | $64.35K | $21.06 Million | -0.55pp |
| 2024-12-31 | 0.86% | $64.74K | $7.54 Million | -0.16pp |
| 2023-12-31 | 1.02% | $79.31K | $7.78 Million | +0.33pp |
| 2022-12-31 | 0.69% | $75.80K | $10.93 Million | -0.10pp |
| 2021-12-31 | 0.79% | $108.15K | $13.70 Million | -7.27pp |
| 2020-12-31 | 8.06% | $1.19 Million | $14.77 Million | -40.50pp |
| 2019-12-31 | 48.57% | $3.36 Million | $6.93 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $6.60 Million | -- |
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more